The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Guzman Alonso
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma
 
Irene Moreno
Consulting or Advisory Role - BOXER CAPITAL LLC; ELLIPSES PHARMA; Guidepoint Global
Speakers' Bureau - Getthi group
Research Funding - DIGICORE (IDEAL4RWE); FUNDACIÓN INTHEOS
 
Kristoffer Rohrberg
Honoraria - MSD; MSD
Consulting or Advisory Role - Abbvie; Genmab
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merus (Inst); MonTa Biosciences (Inst); MSD (Inst); Navire (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Symphogen (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst)
 
Valentina Gambardella
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amcure (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Samuel Lim
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Sravanthi Cheeti
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Peiqing Yu
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Aneta Swat
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Fabiola Amair-Pinedo
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.